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The von WiHebrand Factor Domain-Mediating Botrocetin4nduced Binding
to Glycoprotein LB Lies Between Vat449 and Lys728
By Yoshihiro Fujimura, Linda Z. Holland, Zaverio M. Ruggeri, and Theodore S. Zimmerman
Botrocetin, a component of Bothrops jararaca venom.
induces von Willebrand factor (vWF)-dependent platelet
agglutination and has been proposed as an alternative
agent to ristocetin for evaluating vWF function. However.
important differences between the vWF-platelet interac-
tions induced by these two agents have suggested that
different regions of vWF and the platelet may be involved
in the interactions induced by the two agonists. We have
recently demonstrated that binding of vWF to the platelet
glycoprotein (GP) lb receptor. either induced by ristocetin
or as occurs spontaneously with asialo-vWF or vWF from
IIB von Willebrand disease, is mediated by a domain resid-
ing on a 52/48-kilodalton (kD) tryptic fragment of vWF.
V ON WILLEBRAND FACTOR (vWF) plays an essen-
tial role in primary hemostasis and circulates in blood
as a series of multimers composed of a 2,050-amino acid
residue subunit.’2 The ability of vWF to support ristocetin-
induced platelet agglutination has been widely used to assess
vWF function in vitro.’
Read et al and Brinkhous and Read45 have found that
botrocetin, a component of venom from the species Bothrops
jararaca, causes vWF-dependent platelet agglutination.
They suggested that botrocetin could substitute for ristocetin
in an assay of vWF function.5 However, several important
differences between these two agonists have been noted.
Plasma from patients with type hA vWD lacks the largest
vWF multimers and has markedly decreased levels of risto-
cetin cofactor activity. However, the botrocetin cofactor
activity is normal in such plasma.6’ Botrocetin can function
in the presence of negatively charged heparin4 or the ristoce-
tin analogue vancomycin,’ whereas ristocetin does not. Plate-
let-rich plasma (PRP) from patients with Bernard-Soulier
syndrome, in which qualitative and quantitative abnormali-
ties of platelet glycoprotein lb (GPIb) are noted, shows
partial platelet aggregation with botrocetin but a total lack of
platelet agglutination by ristocetin.’ Based on these observa-
tions, Howard et al have postulated that different functional
sites on both the platelet and vWF molecule are involved in
interactions induced by ristocetin and botrocetin.’
Recently we have determined that the GPIb-binding
domain of human vWF resides on a tryptic fragment that
extends from amino acid residue 449 to 728 of the vWF
subunit.89 We have demonstrated that this fragment directly
binds to the GPIb receptor without any platelet agonist and
independently of platelet metabolism.8’0 In this paper we
present evidence that the botrocetin-induced vWF binding to
platelets is mediated by a domain that also lies between
amino acid residues 449 to 728 and is close to if not identical
with that mediating ristocetin-inducing binding. We also
show that binding is to the GPIb receptor.
MATERIALS AND METHODS
Carrier-free Na [1251] was obtained from Amersham Corp (Ar-
lington Heights, IL). Ristocetin, apyrase, trypsin (bovine pancreatic
type 1, 11,300 to 15,000 U/mg), and B jararaca venom were
purchased from Sigma Chemical Co (St Louis). Crystallized bovine
This fragment extends from amino acid residue Val (449) to
Lys (728). We have now found that this 52/48-kD fragment
blocks botrocetin-induced binding of vWF to platelets and
completely inhibits botrocetin-induced platelet agglutina-
tion. These results provide evidence that the vWF
domain-mediating. botrocetin-induced platelet agglutina-
tion lies within the region delimited by this fragment and is
therefore close to or identical with that which mediates
ristocetin-induced binding and spontaneous binding of vWF
to platelet GPIb. Anti-GPlb monoclonal antibodies also
blocked agglutination. which showed that botrocetin, like
ristocetin, induces binding of vWF to the GPlb receptor.
a 1987 by Grune & Stratton, Inc.
serum albumin (BSA) was obtained from Calbiochem-Behring Corp
(La Jolla, CA). Leupeptin was supplied by Chemicon (El Segundo,
CA). Iodogen was from Pierce Chemical Co (Rockford, IL). Other
reagents were of the best grade commercially available.
Purification of botrocetin. Venom coagglutinin (botrocetin)
was purified from B jararaca venom with modifications of the
method of Read et al4 as follows: crude venom was dissolved in 0.02
mol/L Tris-HC1 0.1 mol/L NaCl buffer, pH 7.35, then applied to a
high-performance liquid chromatography (HPLC) anion-exchange
column (Mono Q column; Pharmacia Fine Chemicals, Uppsala,
Sweden) equilibrated with the same buffer. After extensive washing,
the column was eluted with a linear salt gradient (0. 1 to 0.7 mol/L
NaCI) at 1.0 mL/min for 30 minutes. Fractions that contained
platelet coagglutinin activity but were devoid of thrombinlike activ-
ity were pooled and dialyzed against 0.05 mol/L Tris-HCI-O. IS
mol/L NaC1 buffer, pH 7.3 (TBS), at 4#{176}C overnight and then frozen
at - 70#{176}C until used.
Preparation ofhighly purified vWF. Highly purified vWF was
isolated from cryoprecipitate (the generous gift of the American Red
Cross, Bethesda, MD) as previously described.”
Radiolabeling of proteins. [1251] radiolabeling was performed
with the lodogen method.’2 Free [1251] was removed by a disposable
Sephadex G-25 column (PD-b, Pharmacia). The labeled vWF
preparations had a specific activity of 0.28 to 0.92 mCi/mg.
Trypsin cleavage of vWF and separation of fragments. The
methods used have been recently reported in detail.8 Trypsin diges-
tion was performed by mixing 1 mg of vWF with 2,500 units of
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binding to platelets were determined at room temperature by
enzyme and incubating for two hours at 37#{176}C, pH 7.0. The
fragments generated were separated by HPLC size exclusion into six
main fractions as described.8
The isolation of the 52/48-kilodalton (kD) doublet as well as other
fragments of I 3 kD, 22 kD, 41 kD, and 55 kD was performed by
HPLC chromatofocusing and size exclusion chromatography in the
presence of 6 mol/L urea after reduction and S-carboxymethylation
of each fraction.8 All purified tryptic polypeptides were dialyzed
against TBS, pH 7.3, and stored at -70#{176}C until use.
Monoclonal antibodies. Murine monoclonal antibodies to GPIb
were AP1 (the generous gift of Dr Robert Montgomery, Milwau-
kee), LJ-Ibl, and LJ-Ibl2, which have been described and charac-
terized previously.”4 Murine monoclonal antibodies to GPIIb/IIIa
were U-PS and LJ-CP8, which have also been described previous-
ly.”6 IgGs were purified from ascites fluid by protein A-Sepharose
CL-6B (Pharmacia) affinity chromatography according to Ey et
al.”
Preparation of washed. gel-filtered platelets and formalin-fixed
platelets. PRP from fresh acid-citrate-dextrose-blood from nor-
mal volunteers was obtained as described.8 Apyrase was added to the
PRP at a final concentration of 5 adenosine triphosphatase U/mL.
Washed, gel-filtered platelets were prepared by a combination of
BSA density gradient centrifugation’8 and Sepharose CL-2B gel
filtration’9 as described.8 Washed, gel-filtered platelets were sus-
pended in calcium-free Tyrode’s buffer containing 0.1% BSA, pH
7.3.
Formalin-fixed platelets were prepared by overnight fixation of
gel-filtered platelets with 1% formalin.￿#{176}Formalin-fixed platelets
were washed three times with TBS, suspended in TBS, pH 7.3,
containing 0.02% NaN, and 10 ￿ig/mL leupeptin, and stored at
4#{176}C.
Botrocetin-induced binding off25mJvWF toformalin-fixed plate-
lets. Assays were performed in an incubation volume of 125 cL in
plastic Eppendorf tubes. In most experiments, [‘25IIvWF, formalin-
fixed platelets, and botrocetin were added to the tubes at final
concentrations of S ￿cg/mL, l08/mL, and S zg/mL, respectively. For
competitive inhibition studies, various ligands dissolved in TBS, pH
7.3, were added to the incubation mixture at concentrations
described in Results. After 30 minutes’ incubation at room tempera-
ture, two S0-￿L aliquots of the mixture were layered over 20%
sucrose cushions (300 ￿L) in 500-zL Sarstedt microfuge tubes
(Princeton, Ni), and bound ligand was separated from free ligand by
a four-minute centrifugation at 12,000 g in a Beckman Microfuge B
(Palo Alto, CA). The tube tips containing bound ligand were
amputated and counted in a gamma counter. Nonspecific and
nonsaturable binding, determined in the presence of a 50-fold excess
of unlabeled vWF added together with the labeled ligand, was less
than I 5% of total binding. Specific binding was calculated by
subtracting nonspecific binding from the total. The 50% inhibition
constant (IC,,,) was that concentration of competing ligand that
inhibited the specific binding of [‘251]vWF by 50%.
Platelet aggregation studies. They carried out at a final platelet
concentration of 3 to 3.5 x 108/mL in a Lumi aggregometer
(Chrono-Log Corp. Havertown, PA) with 0.3 to 0.5 mL of washed,
gel-filtered platelets or formalin-fixed platelets.
Protein concentration. The concentration of purified mono-
clonal IgG was calculated from absorbence at 280 nm and an
extinction coefficient of E￿,, - 14.3. Concentrations of other
proteins were measured by the method of Bradford2’ with BSA as a
standard.
RESULTS
Botrocetin-induced binding of vWF to platelets. The
concentrations of botrocetin that induced maximum vWF
adding increasing amounts of botrocetin to a mixture con-
taming fixed amounts of [‘251]vWF (5 ￿tg/mL) and formalin-
fixed platelets (l08/mL). Maximum binding occurred
between 2 and 10 ￿g/mL of botrocetin. At concentrations
higher than 10 ￿zg/mL the binding was reduced (not shown).
Thus, a concentration of 5 jzg/mL of botrocetin was chosen
for binding assays.
[‘251]vWF binding to formalin-fixed platelets in the pres-
ence of botrocetin was measured at 4#{176}C, 23#{176}C, and 37#{176}C.
The binding was almost maximum after 15 minutes’ incuba-
tion, and there were no differences in the extent and rate of
[‘25I]vWF binding at the different temperatures (not shown).
Therefore, all the succeeding experiments were performed at
room temperature with 30 minutes’ incubation time.
To determine when the binding was saturable, [‘25I]vWF
(3 to 197 sg/mL) was incubated with formalin-fixed plate-
lets in the presence of botrocetin (Fig 1). The data were
evaluated by Scatchard analysis with the computerized
program LIGAND22 (Fig 1, inset). The molecular mass of
the vWF subunit (275 kD) was substituted for that of the
native, polydisperse, multimerized molecule. The data points
fit a straight line, which indicates the existence of a single
class of binding sites. The binding was saturable, and a total
of 1.60 ￿ig of vWF bound to i0￿ platelets with an apparent
dissociation constant (Kd) of 3.43 x lO_8 mol/L (9.43
￿ig/mL). This value is similar, though slightly higher, to that
reported for ristocetin-induced binding.2’
When [‘251]vWF (5 ,ug/mL) was mixed with various
amounts of unlabeled vWF and formalin-fixed platelets
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Fig 1 . Saturation curve of vWF binding to fixed platelets.
Increasing amounts of [12’IJvWF (0.28 mCi/mg). as indicated on the
abscissa, were mixed with formalin-fixed platelets (10’Imi); then
botrocetin (5 gsglmi) was added and incubated for 30 minutes at
room temperature. The amount of [‘￿1lvWF bound to formalin-
fixed platelets was then measured as described in Materials and
Methods. The values shown in this graph represent total binding.
The inset shows a Scatchard-type plot of the experimental data
obtained by using the computer-assisted program LIGAND and the
points represent specific binding by subtracting the nonspecific
binding (calculated as a fitted parameter) from the total binding.
The best fit for the experimental points was represented by a
straight line. which suggested the existence of a single class of
noninteracting binding sites. The relevant binding parameters for
this experiment were as folows: [‘2￿1JvWF bound at saturation.
1.69 gig/b5 platelets; K￿. 3.43 x 10’ mol/L (calculated per vWF
subunit and assuming a molecular mass of 275 kD); nonsaturable
(nonspecific) binding. 0; B/F. bound/free.
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(lOt/mL) and binding was initiated by botrocetin, more than
95% of bound radioactivity was displaced by a 50-fold excess
of unlabeled ligand (not shown).
The effect of tryptic fragments on botrocetin-induced
f’25IJvWF binding to platelets. Five tryptic fragments of
vWF that had been reduced and S-carboxymethylated were
evaluated for their effect on botrocetin-induced binding of
vWF to platelets. The NH2-terminal residues of these frag-
ments are as follows89: the 52/48-kD doublet, Val￿9; 13 kD,
Gln2￿; 22 kD, Val,927; 41 kD, Thr,,52 and 55 kD, Asn730. The
COOH-terminus of the 52/48-kD fragment corresponded to
Lys728.9 Based on a 275-kD molecular mass for the vWF
subunit, these fragments represent -65% of the entire sub-
unit molecule.
In competitive binding assays, the 52/48-kD fragment
completely inhibited [‘251]vWF binding to platelets at a
concentration of -2 zmol/L with an IC,0 of 0.25 .imol/L.
The other fragments of vWF did not inhibit at concentrations
-50 ￿tmol/L (Fig 2).
The 52/48-kD fragment also prevented botrocetin-
induced platelet aggregation in a dose-dependent manner,
with aggregation completely abolished at a concentration of
150 ￿tg/mL (3 j￿mol/L) (Fig 3). These results indicate that a
domain of vWF within the 52/48-kD fragment is necessary
for botrocetin-induced platelet agglutination.
The effect of monoclonal antibodies directed against
GPJb and GPIIb/IIIa on botrocetin-induced platelet aggre-
gation/agglutination. To determine whether botrocetin-
induced agglutination required binding of vWF to GPIb,
monoclonal antibodies directed against GPIb were investi-
gated for their ability to block botrocetin-induced platelet
agglutination. The two antibodies to GPIb that blocked
ristocetin-induced platelet agglutination (AP-1 and Li-lb 1)
also blocked botrocetin-induced agglutination, whereas
another anti-GPIb antibody not affecting ristocetin-induced
agglutination (LJ-1b12) had no affect on botrocetin-induced
- 0.1 1 10 100
Concentration of Competing Ligands
(tiM)
Fig 2. Inhibition of botrocetin-induced vWF binding to fixed
platelets by the 52/48-kD fragment. [1211VWF (5 pg/mi). formalin-
fixed platelets (10/mi), and various concentrations of reduced
and alkylated 52/48-kD (0 0). 41-kD (#{149} #{149}). 22-kD (#{149} #{149}).
13-kD (v v) and 55-kD (A A) tryptic fragments of vWF were
incubated for 30 minutes at room temperature after the addition
of botrocetin (5 ￿sg/mi). then platelet-bound radioactivity was
measured. After subtraction of nonspecific binding. the specific
binding was expressed as percentages.
Fig 3. Inhibition of botrocetin-
induced platelet aggregation by the
52/48-kD fragment. Formalin-fixed
platelets (3 x 10￿/g￿L), purified vWF (5
￿sg/mL). and various concentration of
a 52/48-kD fragment were mixed in a
cuvette for five minutes at 37’C; then
botrocetin (5 pg/mi) was added to
initiate the platelet agglutination.
52/48 kOa
I (￿.iM)
agglutination (Fig 4). Monoclonal antibodies to GPIIb/IIIa
that blocked the binding of fibrinogen and vWF (LJ-CP8) or
vWF alone (LJ-P5) to this receptor had no effect on botroce-
tin-induced agglutination.
DISCUSSION
We have previously demonstrated that the 52/48-kD
tryptic fragment of vWF contained the domain that binds to
the platelet GPIb receptor. This was true whether binding
occurred spontaneously, as is the case for asialo-vWF and
vWF from LIB vWD,24 or binding of normal vWF was
induced by ristocetin.8” This 52/48-kD fragment begins
with Val￿9 and ends with Lys7289; it binds directly to the
GPIb molecule without any platelet agonist, and its binding
is independent of platelet metabolism.’0 The ability of this
fragment to block botrocetin-induced binding to platelets in
the experiments reported here shows that the domain of vWF
that binds to the GPIb receptor in response to botrocetin falls
between residues Val￿9 and Lys728.
Monoclonal antibodies to GPIb that block ristocetin-
induced platelet agglutination also blocked botrocetin-
induced platelet agglutination. This demonstrated that
I I
LJ1b12 ￿
LJCP8
LJP5
Ty B
Fig 4. Inhibition of botrocetin-induced platelet agglutination
by monoclonal antibodies to GPlb. Purified monoclonal lgGs
against GPlb (A) and the GPllb/lIIa complex (B) were incubated
with washed, gel-filtered platelets (3.0 x 1O/￿ti) and purified
vWF (5 gsg/mL) for five minutes at 37’C. Botrocetin was added at
the time indicated by arrows. The anti-GPlb monoclonal antibodies
AP-1 (50 ￿sg/mi) and LJ-lbl (1.000 ag/mi) produced essentially
complete inhibition of botrocetin-induced agglutination. whereas
LJ-1b12 (1.000 gig/mi) did not. Neither of the anti-GPIIb/llla
antibodies U-CP8 (200 gig/mi) and LJ-P5 (700 ag/mi) had an
effect. Purified antithyroglobulin monoclonal antibody (T’y) (1.000
sg/mi) served as a control.
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botrocetin, like ristocetin, caused binding of vWF to GPIb.
However, Howard et al’ reported that even though people
with Bernard-Soulier syndrome are congenitally deficient in
GPIb, their platelets were agglutinated by botrocetin. This
suggested that an additional platelet binding site for vWF
may exist. Our data do not exclude this possibility. However
they do make GPIIb/IIIa an unlikely candidate for the
secondary site.
Botrocetin induces platelet agglutination in hA vWD
PRP, whereas ristocetin does not. Thus botrocetin cannot be
used as a diagnostic reagent for this and perhaps other vWD
variants. However, the ability of botrocetin to induce platelet
agglutination with IIA vWF, and thus in the absence of large
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